<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34482628</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1552-5279</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title>
          <ISOAbbreviation>Alzheimers Dement</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Epigenomic features related to microglia are associated with attenuated effect of APOE ε4 on Alzheimer's disease risk in humans.</ArticleTitle>
        <Pagination>
          <StartPage>688</StartPage>
          <EndPage>699</EndPage>
          <MedlinePgn>688-699</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/alz.12425</ELocationID>
        <Abstract>
          <AbstractText>Not all apolipoprotein E (APOE) ε4 carriers who survive to advanced age develop Alzheimer's disease (AD); factors attenuating the risk of ε4 on AD may exist. Guided by the top ε4-attenuating signals from methylome-wide association analyses (N = 572, ε4+ and ε4-) of neurofibrillary tangles and neuritic plaques, we conducted a meta-analysis for pathological AD within the ε4+ subgroups (N = 235) across four independent collections of brains. Cortical RNA-seq and microglial morphology measurements were used in functional analyses. Three out of the four significant CpG dinucleotides were captured by one principal component (PC1), which interacts with ε4 on AD, and is associated with expression of innate immune genes and activated microglia. In ε4 carriers, reduction in each unit of PC1 attenuated the odds of AD by 58% (odds ratio = 2.39, 95% confidence interval = [1.64,3.46], P = 7.08 × 10<sup>-6</sup> ). An epigenomic factor associated with a reduced proportion of activated microglia (epigenomic factor of activated microglia, EFAM) appears to attenuate the risk of ε4 on AD.</AbstractText>
          <CopyrightInformation>© 2021 the Alzheimer's Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Yiyi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olah</LastName>
            <ForeName>Marta</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smith</LastName>
            <ForeName>Rebecca</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>College of Medicine and Health, University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oatman</LastName>
            <ForeName>Stephanie R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Allen</LastName>
            <ForeName>Mariet</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pishva</LastName>
            <ForeName>Ehsan</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>College of Medicine and Health, University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menon</LastName>
            <ForeName>Vilas</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ertekin-Taner</LastName>
            <ForeName>Nilüfer</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Mayo Clinic Florida, Jacksonville, Florida, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lunnon</LastName>
            <ForeName>Katie</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>College of Medicine and Health, University of Exeter Medical School, Exeter University, Exeter, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bennett</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Klein</LastName>
            <ForeName>Hans-Ulrich</ForeName>
            <Initials>HU</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Jager</LastName>
            <ForeName>Philip L</ForeName>
            <Initials>PL</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Translational &amp; Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cell Circuits Program, Broad Institute, Cambridge, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AG043617</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG042210</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG036042</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG036836</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG032990</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RC2 AG036547</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 AG016574</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 ES017155</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>KL2 RR024151</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08 AG034290</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U24 NS072026</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 AG19610</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG043617</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG042210</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG036042</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG036836</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AG032990</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>RC2 AG036547</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P50 AG016574</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 ES017155</GrantID>
            <Acronym>ES</Acronym>
            <Agency>NIEHS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>KL2 RR024151</GrantID>
            <Acronym>RR</Acronym>
            <Agency>NCRR NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>K08 AG034290</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U24 NS072026</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 AG19610</GrantID>
            <Acronym>AG</Acronym>
            <Agency>NIA NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Alzheimers Dement</MedlineTA>
        <NlmUniqueID>101231978</NlmUniqueID>
        <ISSNLinking>1552-5260</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053327" MajorTopicYN="Y">Apolipoprotein E4</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057890" MajorTopicYN="N">Epigenomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alzheimer's disease</Keyword>
        <Keyword MajorTopicYN="N">apolipoprotein E</Keyword>
        <Keyword MajorTopicYN="N">epigenome</Keyword>
        <Keyword MajorTopicYN="N">microglia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>5</Day>
          <Hour>21</Hour>
          <Minute>8</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34482628</ArticleId>
        <ArticleId IdType="doi">10.1002/alz.12425</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Farrer LA. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-1356.</Citation>
        </Reference>
        <Reference>
          <Citation>Sherva R, Farrer LA. Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer's disease. Curr Psychiatry Rep. 2011;13:138-146.</Citation>
        </Reference>
        <Reference>
          <Citation>Lambert J-C, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45:1452-1458.</Citation>
        </Reference>
        <Reference>
          <Citation>Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. Nat Genet. 2019;51:414-430.</Citation>
        </Reference>
        <Reference>
          <Citation>Meyer MR, Tschanz JT, Norton MC, et al. APOE genotype predicts when-Not whether-One is predisposed to develop Alzheimer disease. Nat Genet. 1998;19:321-322.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma Y, Ordovas JM. The integration of epigenetics and genetics in nutrition research for CVD risk factors. Proc Nutr Soc. 2017;76:333-346.</Citation>
        </Reference>
        <Reference>
          <Citation>De Jager PL, Ma Y, Mccabe C, et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer's disease research. Sci Data. 2018;5:180142.</Citation>
        </Reference>
        <Reference>
          <Citation>De Jager PL, Srivastava G, Lunnon K, et al. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17:1156-1163.</Citation>
        </Reference>
        <Reference>
          <Citation>Patrick ET, Taga M, Ergun A, et al. Deconvolving the contributions of cell-type heterogeneity on cortical gene expression. bioRxiv. 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Felsky D, Roostaei T, Nho K, et al. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nat Commun. 2019;10:409.</Citation>
        </Reference>
        <Reference>
          <Citation>Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21:108-117.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma Y, Jun GR, Zhang X, et al. Analysis of whole-exome sequencing data for Alzheimer disease stratified by APOE genotype. JAMA Neurol. 2019;76(9):1099-1108.</Citation>
        </Reference>
        <Reference>
          <Citation>Strickland SL, Reddy JS, Allen M, et al. MAPT haplotype-stratified GWAS reveals differential association for AD risk variants. Alzheimers Dement. 2020;16(7):983-1002.</Citation>
        </Reference>
        <Reference>
          <Citation>Lunnon K, Smith R, Hannon E, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci. 2014;17:1164-1170.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith RG, Hannon E, De Jager PL, et al. Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. Alzheimers Dement. 2018;14:1580-1588.</Citation>
        </Reference>
        <Reference>
          <Citation>Zou F, Chai HS, Younkin CS, et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet. 2012;8:e1002707.</Citation>
        </Reference>
        <Reference>
          <Citation>Allen M, Carrasquillo MM, Funk C, et al. Human whole genome genotype and transcriptome data for Alzheimer's and other neurodegenerative diseases. Sci Data. 2016;3:160089.</Citation>
        </Reference>
        <Reference>
          <Citation>Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984;34:939-944.</Citation>
        </Reference>
        <Reference>
          <Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2.</Citation>
        </Reference>
        <Reference>
          <Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837-1844.</Citation>
        </Reference>
        <Reference>
          <Citation>Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiol Aging. 2014;35:819-826.</Citation>
        </Reference>
        <Reference>
          <Citation>A Bennett D, A Schneider J, Arvanitakis Z, S Wilson R. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9:628-645.</Citation>
        </Reference>
        <Reference>
          <Citation>A Bennett D, A Schneider J, S Buchman A, L Barnes L, A Boyle P, S Wilson R. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9:646-663.</Citation>
        </Reference>
        <Reference>
          <Citation>White CC, Yang H-S, Yu L, et al. Identification of genes associated with dissociation of cognitive performance and neuropathological burden: multistep analysis of genetic, epigenetic, and transcriptional data. PLoS Med. 2017;14:e1002287.</Citation>
        </Reference>
        <Reference>
          <Citation>Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics. 2013;14:293.</Citation>
        </Reference>
        <Reference>
          <Citation>Allen M, Burgess JD, Ballard T, et al. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci. Acta Neuropathol. 2016;132:197-211.</Citation>
        </Reference>
        <Reference>
          <Citation>Mostafavi S, Gaiteri C, Sullivan SE, et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. Nat Neurosci. 2018;21:811-819.</Citation>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447-D452.</Citation>
        </Reference>
        <Reference>
          <Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc. 1995;57:289-300.</Citation>
        </Reference>
        <Reference>
          <Citation>Won H, De La Torre-Ubieta L, Stein JL, et al. Chromosome conformation elucidates regulatory relationships in developing human brain. Nature. 2016;538:523-527.</Citation>
        </Reference>
        <Reference>
          <Citation>Lesaffre E, Albert A. Partial separation in logistic discrimination. J R Stat Soc Series B Methodol. 1989;1:109-116.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
